More Galleries
7 hot businesses to start now It's hard to predict what businesses will take off, but these startup ideas have been drawing tons of interest from entrepreneurs and their customers on Thumbtack.com. More
How will a minimum wage hike hit businesses? Thirteen states increased the minimum wage on Jan. 1, and President Obama supports raising the federal rate to $10.10. 4 small business owners weigh in on how an increase would affect them. More
America's favorite businesses From a science camp for girls to a kombucha brewer, communities around the country voted on their favorite small businesses. These 12 came out on top, each scoring a $250,000 grant from Chase and a trip to Google's headquarters. More

Special Offer
9 of 36
BACK NEXT
A nanotherapy for liver cancer
A nanotherapy for liver cancer
Jordi de los Pinos, Elisabet de los Pinos and Zeid Barakat
Team name: Aura Biosciences

School name: MIT, Sloan School of Management

Team members: Elisabet de los Pinos, Jordi de los Pinos, Zeid Barakat

Concept: Patents on many drugs used to treat liver cancer (which kills 650,000 people each year) will expire within the next five years. Aura Biosciences aims to give pharmaceutical companies such as Sanofi-Aventis and Eli Lilly a chance to extend those patents by licensing the use of tiny "nanosmart" particles, only 20 nanometers wide, that deliver the drugs directly to tumor cells, reducing patient side effects while increasing efficacy and survival rates.

The company also plans to push for an "orphan drug" designation from the the U.S. Food & Drug Administration and the European Medicines Agency that may reduce required trial times, increase government support for development and marketing, and grant short-term market exclusivity. The technology is highly experimental: Much of Aura's funding will cover trials necessary to gain regulatory approval and convince skeptical drug manufacturers. But Phase III licensing agreements are frequently highly lucrative, with the potential for extensive royalties as well as up-front payments in the tens or hundreds of millions.

Timeline: The team plans to start Phase I European trials in 2009 and Phase II trials in the U.S. in 2010, with the goal of licensing its technology to a major pharmaceutical manufacturer by 2012. - Rose Fox

NEXT: Easier TB diagnosis

Last updated May 02 2008: 11:51 AM ET
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer LIBOR Warning: Neither BBA Enterprises Limited, nor the BBA LIBOR Contributor Banks, nor Reuters, can be held liable for any irregularity or inaccuracy of BBA LIBOR. Disclaimer. Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.